Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

The cards we feature here are from partners who compensate us when you are approved through our site, and this may impact how or where these products appear. We don’t cover all available credit cards, ...

In a report released on January 13, Faisal Khurshid from Leerink Partners reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report). The company’s shares closed yesterday at $54.16.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

On Monday, Leerink Partners upgraded Align Technology (NASDAQ:ALGN) shares from Market Perform to Outperform and increased the price target to $280 from $235. The firm’s analysts cited an improved ...

On Monday, Leerink Partners analyst Michael Cherny upgraded shares of Quest Diagnostics (NYSE:DGX) stock from Market Perform to Outperform, increasing the price target from $169 to $174. The upgrade ...